We are live on ! Find out more
FOMX

Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX

Delisted

FOMX was delisted on the 6th of March, 2020.

Back to rankings

56 hedge funds and large institutions have $108M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less capital invested

Capital invested by funds: $117M → $108M (-$9.74M)

15% less funds holding

Funds holding: 66 → 56 (-10)

22% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 18

39% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 23

Holders
56
Holders Change
-10
Holders Change %
-15.15%
% of All Funds
1.49%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
14
Reduced
18
Closed
23
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$5.28M
2
DM
Deerfield Management
New York
+$2.21M
3
GPP
Great Point Partners
Connecticut
+$1.82M
4
NC
Nexthera Capital
New York
+$964K
5
OM
Opaleye Management
Massachusetts
+$697K

Top Sellers

Rank Fund Capital Flow
1
SAM
Senzar Asset Management
New York
-$6.64M
2
BFA
BlackRock Fund Advisors
California
-$3.96M
3
State Street
State Street
Massachusetts
-$1.91M
4
Northern Trust
Northern Trust
Illinois
-$1.34M
5
JP Morgan Chase
JP Morgan Chase
New York
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
PVI
26
Pura Vida Investments
New York
$648K – – –
PP
27
Paloma Partners
Connecticut
$585K +$612K +92,200 New
CS
28
Credit Suisse
Switzerland
$576K +$602K +90,722 New
Deutsche Bank
29
Deutsche Bank
Germany
$569K +$236K +35,586 +66%
LCM
30
Laurion Capital Management
New York
$415K +$434K +65,400 New
Baird Financial Group
31
Baird Financial Group
Wisconsin
$374K -$167K -25,170 -30%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$333K -$52.4K -7,893 -13%
Goldman Sachs
33
Goldman Sachs
New York
$292K +$227K +34,195 +288%
TC
34
TFS Capital
Pennsylvania
$222K +$232K +34,930 New
ProShare Advisors
35
ProShare Advisors
Maryland
$145K -$16K -2,405 -10%
LP
36
LMR Partners
United Kingdom
$112K +$117K +17,600 New
AGM
37
Alpine Global Management
New York
$109K +$113K +17,092 New
Morgan Stanley
38
Morgan Stanley
New York
$98K +$54.1K +8,147 +112%
VanEck Associates
39
VanEck Associates
New York
$94K -$2.83K -426 -3%
PPCM
40
Pillar Pacific Capital Management
California
$89K – – –
Geode Capital Management
41
Geode Capital Management
Massachusetts
$88K -$161K -24,314 -64%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$85K +$89.2K +13,448 New
Bank of America
43
Bank of America
North Carolina
$79K +$82.2K +12,381 New
FFA
44
First Foundation Advisors
California
$75K +$78.4K +11,819 New
PPA
45
Parametric Portfolio Associates
Washington
$71K +$5.53K +834 +8%
TRCT
46
Tower Research Capital (TRC)
New York
$47K +$47.6K +7,173 +2,544%
Citigroup
47
Citigroup
New York
$36K -$125K -18,818 -77%
PCM
48
Penserra Capital Management
California
$19K +$2.45K +369 +14%
Barclays
49
Barclays
United Kingdom
$17K -$4.4K -663 -19%
Victory Capital Management
50
Victory Capital Management
Texas
$11K +$465 +70 +4%
1
2
3 4

FOMX Hedge Fund Activity: Q2 2016 in Review

56 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q2 2016, worth a combined $108M — down 8.3% from $117M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of FOMX and 14 opened new positions — a net loss of 9 holders — while 18 trimmed existing stakes and 14 added.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $5.28M. The largest seller was Senzar Asset Management, cutting an estimated $6.64M.

  • 56 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q2 2016, down from 66 in Q1 2016.
  • Funds reported $108M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q2 2016, down 8.3% quarter-over-quarter.
  • 14 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q2 2016 and 23 closed out, a net change of -9 holders.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q2 2016 was Perceptive Advisors, an estimated $5.28M added.
  • The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q2 2016 was Senzar Asset Management, an estimated $6.64M sold.

Based on aggregated 13F filings for Q2 2016.